7 patents
Utility
Maytansinoid-based Drug Delivery Systems
7 Dec 23
The present subject matter provides for albumin-binding prodrugs, maytansinoid-based compounds, and uses thereof.
Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
Filed: 21 Dec 22
Utility
Maytansinoid-based drug delivery systems
7 Feb 23
The present subject matter provides for albumin-binding prodrugs, maytansinoid-based compounds, and uses thereof.
Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
Filed: 30 Nov 18
Utility
Delivery Systems for Controlled Drug Release
26 Jan 23
Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
Filed: 3 Jun 22
Utility
Delivery systems for controlled drug release
12 Jul 22
Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
Filed: 17 Jun 16
Utility
Albumin-binding prodrugs of auristatin E derivatives
5 Jul 22
The present disclosure provides for albumin-binding prodrugs of auristatin E derivatives and uses thereof.
Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
Filed: 30 Nov 18
Utility
Cytotoxic agents for the treatment of cancer
4 Jan 21
The present invention relates to a method of treating brain cancer comprising administering a therapeutically effective substance to a patient, wherein the therapeutically effective substance comprises: (I), or a pharmaceutically acceptable salt thereof, wherein X is a moiety that can be cleaved hydrolytically or enzymatically in the body of the patient in a pH-dependent manner.
Daniel Levitt
Filed: 18 Feb 19
Utility
Cytotoxic Agents for the Treatment of Cancer
20 Nov 19
The present invention relates to a method of treating brain cancer comprising administering a therapeutically effective substance to a patient, wherein the therapeutically effective substance comprises: (I), or a pharmaceutically acceptable salt thereof, wherein X is a moiety that can be cleaved hydrolytically or enzymatically in the body of the patient in a pH-dependent manner.
Daniel Levitt
Filed: 18 Feb 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first